# Black Diamond Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2020

- Company: [Black Diamond Therapeutics, Inc.](/companies/bdtx.md) (CIK 1701541)
- Form: 10-Q
- Filed: 2020-11-10
- Accepted by EDGAR: Nov 10, 2020, 07:17 ET
- Period: 2020-09-30
- Accession: 0001701541-20-000032
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1701541/000170154120000032/bdtx-20200930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1701541/000170154120000032/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2020-07-01 to 2020-09-30 | $12.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2020-01-01 to 2020-09-30 | $30.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2020-07-01 to 2020-09-30 | −$18.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-01-01 to 2020-09-30 | −$46.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-07-01 to 2020-09-30 | $0 | us-gaap:InterestExpense |
| Interest expense | 9 months, 2020-01-01 to 2020-09-30 | $1.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2020-07-01 to 2020-09-30 | −$17.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-01-01 to 2020-09-30 | −$44.6m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months, 2020-01-01 to 2020-09-30 | −$36.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2020-01-01 to 2020-09-30 | $33.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-09-30 | $56.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-09-30 | $336.4m | us-gaap:AssetsCurrent |
| Total assets | at 2020-09-30 | $346.4m | us-gaap:Assets |
| Current liabilities | at 2020-09-30 | $11.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-09-30 | $19.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-09-30 | $327.3m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1701541/000170154120000032/bdtx-20200930.htm

Filed Nov 10, 2020.
Source: SEC EDGAR, the filing index for accession 0001701541-20-000032. Last ingested by Listed: Nov 10, 2026, 16:37 ET. No prices; not investment advice.
